Pathogenetic Aspects of Brain Lesions in Wilson–Konovalov Disease
https://doi.org/10.21508/1027-4065-2020-65-6-22-28
Abstract
The Wilson–Konovalov disease is the autosomal recessive hereditary disease caused by ATP7B gene mutation. With the mutations of the gene specified, the copper transport is disrupted, which causes its accumulation in the liver cells and neuroglia of the brain. The copper accumulation in the nervous tissue is observed in the period from the first to the fifth decade of life. In addition, this disease affects the metabolism of iron, which accumulates in the astrocytes and macrophages. The accumulation of these metals leads to the morphological changes in the glial cells, as follows: changes in the shape of astrocytes, formation of the transition types of microglia and increase in its size, and edema of the oligodendroglia, and in the severe cases, the decrease in the number of the neurons and destruction of the myelinated fibers.
About the Authors
V. N. Salkov
Research Center of Neurology
Russian Federation
Moscow
Russian Federation
Moscow
R. M. Khudoerkov
Research Center of Neurology
Russian Federation
Moscow
Russian Federation
Moscow
V. S. Sukhorukov
Research Center of Neurology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Aftab A., Walker A., Ashkan K. Wilson’s disease. Lancet 2007; 369(3): 397–408. DOI: 10.1016/s0140-6736(07)60196-2
2. Wilson S.A.K. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295–507.
3. Dziezyc K., Karlinski M., Litwin T., Czlonkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol 2014; 21(2): 332–337. DOI: 10.1111/ene.12320
4. Еремина Е.Ю. Болезнь Вильсона–Коновалова. Вестник современной клинической медицины 2011; 4(1): 40–46. [Eremina E.Yu. Wilson-Konovalow disease. Vestnik sovremennoi klinicheskoi meditsiny 2011; 4(1): 40–46. (in Russ.)]
5. Гончарик И.И. Болезнь Вильсона. Медицинский журнал 2006: 1: 7–9. [Goncharik I.I. Wilson’s disease. Medicinskii zhurnal 2006; 1: 7–9. (in Russ.)]
6. Kaler S.G. Inborn errors of copper metabolism. Handb Clin Neurol 2013; 113: 1745– 1754. DOI: 10.1016/B978-0-444-59565-2.00045-9
7. Brewer G. Harrison’s principles of internal medicine. Band 2. New York, 2008; 2449–2552.
8. Lorincz M.T. Wilson disease and related copper disorders. Handb Clin Neurol 2018; 147: 279–292. DOI: 10.1016/B978-0-444-63233-3.00018-X
9. Мищенко Т.С., Волошин-Гапонов И.К. Современные аспекты болезни Вильсона. Международный неврологический журнал 2015; 2: 20–23. [Mishchenko T.S., Voloshin-Haponov I.K. Current aspects Wilson’s disease. Mezhdunarodnyi nevrologicheskii zhurnal (International Neurological Journal) 2015; 2: 20–23. (in Russ.)]
10. Chaudhry H.S., Anilkumar A.C. Wilson disease. 2019. Database http://pubmed.ncbi.nlm.nih.gov/ Ссылка активна на 07.09.2020.
11. Козлова Н.М., Гвак К.В, Гаджибалаева Л.Ш. Болезнь Вильсона–Коновалова. Сибирский медицинский журнал 2011; 5: 125–129. [Kozlova N.M., Gvak K.V., Gadzhibalayeva L.S. Wilson’s disease. Sibirskii meditsinskii zhurnal (Siberian Scientific Medical Journal) 2011; 5: 125–129. (in Russ.)]
12. Жигальцова О.А., Силивончик Н.Н., Жигальцов А.М., Юдина О.А., Лихачев С.А., Плешко И.В. Внепеченочные проявления болезни Вильсона–Коновалова. Журнал Гродненского государственного медицинского университета 2012; 2: 67–70. [Zhyhaltsova O.A., Silivonchik N.N., Zhihaltsov A.M., Yudina O.A., Likhachev S.A., Pleshko I.V. Extrahepatic manifestations of Wilson s disease. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta 2012; 2: 67–70. (in Russ.)]
13. Kaler S.G. Wilson disease. Cecil’s Textbook of Medicine. Philadelphia: Saunders, 2008; 1593–1595.
14. Przybylkowski A., Gromadzka G., Chabik G., Wierzchowska A., Litwin T., Czlonkowska A. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson’s disease. Funct Neurol 2014; 29: 23–29. DOI: 10.11138/fneur/2014.29.1.023
15. Jellinger K.A. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders. J Neural Transm 2019; 126(8): 997–1027. DOI: 10.1007/s00702-019-02030-y
16. Dusek P., Litwin T., Czlonkowska A. Neurologic impairment in Wilson disease. Ann Transl Med 2019; 7(2): S64. DOI: 10.21037/atm.2019.02.43
17. Xie J-J., Wu Z.-Y. Wilson’s Disease in China. Neurosci Bull 2017; 33(3): 323–330. DOI: 10.1007/s12264-017-0107-4
18. Litwin T., Gromadzka G., Szpak G.M., Jablonka-Salach K., Bulska E., Czlonkowska A. Brain metal accumulation in Wilson’s disease. J Neurol Sci 2013; 329: 55–58. DOI: 10.1016/j.jns.2013.03.021
19. Scheiber I.F., Bruha R., Dusek P. Pathogenesis of Wilson disease. Handb Clin Neurol 2017; 142: 43–55. DOI: 10.1016/B978-0-444-63625-6.00005-7
20. Scheiber I.F., Dringen R. Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes. Neurosci Lett 2011; 498(1): 42–46. DOI: 10.1016/j.neulet.2011.04.058
21. Jadav R., Saini J., Sinha S., Bagepally B., Rao S., Taly A.B. Diffusion tensor imaging (DTI) and its clinical correlates in drug naive Wilson’s disease. Metab Brain Dis 2013; 28(3): 455–462. DOI: 10.1007/s11011-013-9407-1
22. Dong Y., Shi S.S., Chen S., Ni W., Zhu M., Wu Z.Y. The discrepancy between the absence of copper deposition and the presence of neuronal damage in the brain of Atp7b (–/–) mice. Metallomics 2015; 7(2): 283–288. DOI: 10.1039/c4mt00242c
23. Przybylkowski A., Gromadzka G., Wawer A., Bulska E., Jablonka-Salach K., Grygorowicz T. et al. Neurochemical and behavioral characteristics of toxic milk mice: an animal model of Wilson’s disease. Neurochem Res 2013; 38: 2037–2045. DOI: 10.1007/s11064-013-1111-3
24. Terwel D., Loschmann Y.N., Schmidt H.H., Scholer H.R., Cantz T., Heneka M.T. Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model of Wilson’s disease. J Neurochem 2011; 118(1): 105–112. DOI: 10.1111/j.1471-4159.2011.07278.x
25. Klos K.J., Ahlskog J.E., Kumar N., Cambern S., Butz J., Burritt M. et al. Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurol 2006; 67(11): 1984–1989. DOI: 10.1212/01.wnl.0000247037.37807.76
26. Dusek P., Bahn E., Litwin T., Jablonka-Salach K., Luciuk A., Huelnhagen T. et al. Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI – histopathological study. Neuropathol Appl Neurobiol 2017; 43: 514–532. DOI: 10.1111/nan.12341
27. Simmons D.A., Casale M., Alcon B., Pham N., Narayan N., Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia 2007; 55(10): 1074–1084. DOI: 10.1002/glia.20526
28. Andersen H.H., Johnsen K.B., Moos T. Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol Life Sci 2014; 71(9): 1607– 1622. DOI: 10.1007/s00018-013-1509-8
29. Kaneko K., Yoshida K., Arima K., Ohara S., Miyajima H., Kato T. et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol 2002; 61(12): 1069–1077. DOI: 10.1093/jnen/61.12.1069
30. Kruer M.C., Hiken M., Gregory A., Malandrini A., Clark D., Hogarth P. et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011; 134: 947–958. DOI: 10.1093/brain/awr042
31. Gerlach M., Double K.L., Ben-Shachar D., Zecca L., Youdim M.B., Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res 2003; 5: 35–44. DOI: 10.1007/bf03033371
32. Jomova K., Vondrakova D., Lawson M., Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345: 91–104. DOI: 10.1007/s11010-010-0563-x.
33. Zhong W., Huang Z., Tang X. A study of brain MRI characteristics and clinical features in 76 cases of Wilson’s disease. J Clin Neurosci 2019; 59: 167–174. DOI: 10.1016/j.jocn.2018.10.096
34. Zou L., Song Y., Zhou X., Chu J., Tang X. Regional morphometric abnormalities and clinical relevance in Wilson’s disease. Mov Disord 2019; 34(4): 545–554. DOI: 10.1002/mds.27641
35. Mikol J., Vital C., Wassef M., Chappius P.H., Poupon J., Lecharpentier et al. Extensive cortico-subcortical lesions in Wilson’s disease: clinico-pathological study of two cases. Acta Neuropathol 2005; 110(5): 451–458. DOI: 10.1007/s00401-005-1061-1
36. Bertrand E., Lewandowska E., Szpak G.M., Hoogenraad T., Blaauwgers H.G., Czlonkowska A. et al. Neuropathological analysis of pathological forms of astroglia in Wilson’s disease. Folia Neuropathol 2001; 39(2): 73–79.
37. Meenakshi-Sundaram S., Mahadevan A., Taly A.B., Arunodaya G.R., Swamy H.S., Shankar S.K. Wilson’s disease: a clinico-neuropathological autopsy study. J Clin Neurosci 2008; 15(4): 409–417. DOI: 10.1016/j.jocn.2006.07.017
38. Bertrand E., Lechowicz W., Szpak G.M., Lewandowska E., Członkowska A., Dymecki J. Quantitative study of pathological forms of astroglia in Wilson’s disease. Folia Neuropathol 1997; 35(4): 227–232.
39. Lewandowska E., Wierzba-Bobrowicz T., Kosno-Kruszewska E., Lechowicz W., Schmidt-Sidor B., Szpak G.M. et al. Ultrastructural evaluation of activated forms of microglia in human brain in selected neurological diseases (SSPE, Wilson’s disease and Alzheimer’s disease). Folia Neuropathol 2004; 42(2): 81–91.
40. Гулевская Т.С., Чайковская Р.П., Ануфриев П.Л. Патоморфология головного мозга при гепатолентикулярной дегенерации (болезни Вильсона–Коновалова). Анналы клинической и экспериментальной неврологии 2020; 14(2): 50–61. [Gulevskaya T.S., Chaykovskaya R.P., Anufriev P.L. Cerebral pathology in hepatolenticular degeneration (Wilson disease). Annaly klinicheskoi i eksperimental’noi nevrologii (Annals of Clinical and Experimental Neurology) 2020; 14(2): 50–61. (in Russ.)] DOI: 10.25692/ACEN.2020.2.7
41. Poujois A., Mikol J., Woimant F. Wilson disease: brain pathology. Review Handb Clin Neurol 2017; 142: 77–89. DOI: 10.1016/B978-0-444-63625-6.00008-2
42. Nishimuta M., Masui K., Yamamoto T., Ikarashi Y., Tokushige K., Hashimoto E. Copper deposition in oligodendroglial cells in an autopsied case of hepatolenticular degeneration. Neuropathology 2018; 38: 321–328. DOI: 10.1111/neup.12456
43. Niemann N., Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord 2019; 67: 74–89. DOI: 10.1016/j.parkreldis.2019.06.025
44. Евтушенко С.К., Голубева И.Н. Случай ювенильного паркинсонизма у девочки 16 лет. Международный неврологический журнал 2010; 3: 33–35. [Evtushenko S.K., Golubeva I.N. A case juvenile parkinsonism in a 16-year-old girl. Mezhdunarodnyi nevrologicheskii zhurnal (International Neurological Journal) 2010; 3: 33–35. (in Russ.)]
45. Rosencrantz R., Schilsky M. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis 2011; 31(3): 245–259. DOI: 10.1055/с-0031-1286056
46. Bandmann O., Weiss K.H., Kaler S.G. Wilson’s disease and other neurological copper disorders. Lancet Neurol 2015; 14(1): 103–113. DOI: 10.1016/S1474-4422(14)70190-5
47. Bucossi S., Polimanti R., Mariani S., Ventriglia M., Bonvicini C., Migliore S. et al. Association of K832R and R952K SNPs of Wilson’s disease gene with Alzheimer’s disease. J Alzheimer’s Dis 2012; 29(4): 913–919. DOI: 10.3233/JAD-2012-111997
48. Гайкова О.Н., Трофимова Т.Н., Онищенко Л.С., Дмитриев О.В., Емелин А.Ю., Зуева О.В. и др. Морфологические особенности нейронов коры головного мозга при деменции альцгеймеровского типа и сосудистой деменции. Вестник Российской Военно-Медицинской Академии 2012; 3: 193–200. [Gaikova O.N., Trofimova T.N., Onishenko L.S., Dmitriev O.V., Emelin A.Yu., Zueva O.V. et al. Morphological specificities of brain cortex neurons in alzheimer’s type dementia and vascular dementia. Vestnik Rossiyskoi Voenno-Meditsinskoi Academii 2012; 3: 193–200. (in Russ.)]
49. Rajendran R., Minqin R., Ynsa M.D., Casadesus G., Smith M.A., Perry G. et al. A novel approach to the identification and quantitative elemental analysis of amyloid deposits-insights into the pathology of Alzheimer’s disease. Biochem Biophys Res Commun 2009; 382: 91–95. DOI: 10.1016/j.bbrc.2009.02.136
50. Brewer G.J. Copper-2 ingestion, plus increased meat eating leading to increased copper absorption, are major factors behind the current epidemic of Alzheimer’s disease. Nutrients 2015; 7(12): 10053–10064. DOI: 10.3390/nu7125513
51. Fernando M., van Mourik I., Wassmer E., Kelly D. Wilson disease in children and adolescents. Arch Dis Child 2020; 105: 499–505. DOI: 10.1136/archdischild-2018-315705
52. Kodama H., Fujisawa C., Bhadhprasit W. Pathology, clinical features and treatments of congenital copper metabolic disorders – focus on neurologic aspects. Brain and Development 2011; 33(3): 243–251. DOI: 10.1016/j.braindev.2010.10.021
Review
For citations:
Salkov V.N., Khudoerkov R.M., Sukhorukov V.S. Pathogenetic Aspects of Brain Lesions in Wilson–Konovalov Disease. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2020;65(6):22-28. (In Russ.) https://doi.org/10.21508/1027-4065-2020-65-6-22-28
Views:
939
Email this article 